← Leaderboards
Saikrishna Yendamuri
Roswell Park Cancer Institute Corp
$2,302,224
Attributed
$4,584,657
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $861.9K · FY2011–25$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,584,657 · 3
By mechanism
R01$3,423,650 · 1
K23$937,300 · 1
T32$223,707 · 1
Top collaborators
- Joseph Barbi8 shared
- Mary E Reid8 shared
Most similar at Roswell Park Cancer Institute Corp
Same institution · by research overlap
- Mary E Reid$2,296,661
- Joseph Barbi$1,141,217
- Richard J O'Connor$21,371,886
- Maansi Bansal-Travers$2,183,141
- Nicholas John Felicione$469,024
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungHigh RiskMalignant NeoplasmsNon-Small-Cell Lung CarcinomaSerumBloodSurvival RateTissuesEnvironmentTumorResearch PersonnelBiopsySamplingCancer ModelClinical TrialsImmunologicsHigh-Risk CancerAnti-CancerImmuneImmunologic SurveillanceChemopreventionEventCancer RiskCarcinogenesis
Grant awards (14)
Metformin for chemoprevention of lung cancer in obese subjects at high risk$583,338
R01 · FY2025 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$628,294
R01 · FY2024 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$66,036
R01 · FY2024 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$794,005
R01 · FY2023 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$67,940
R01 · FY2023 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$584,429
R01 · FY2022 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$69,151
R01 · FY2022 · CA · contact PI
Metformin for chemoprevention of lung cancer in obese subjects at high risk$630,457
R01 · FY2021 · CA · contact PI
Post-doctoral research training in surgical oncology$223,707
T32 · FY2020 · CA · contact PI
MicroRNA profiling to predict recurrence after resection of early lung cancer$186,130
K23 · FY2016 · CA · contact PI
MicroRNA profiling to predict recurrence after resection of early lung cancer$186,729
K23 · FY2015 · CA · contact PI
MicroRNA profiling to predict recurrence after resection of early lung cancer$187,476
K23 · FY2013 · CA · contact PI
MicroRNA profiling to predict recurrence after resection of early lung cancer$187,965
K23 · FY2012 · CA · contact PI
MicroRNA profiling to predict recurrence after resection of early lung cancer$189,000
K23 · FY2011 · CA · contact PI